<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs), <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="9753">troglitazone</z:chebi>, the synthetic <z:chebi fb="4" ids="48705">agonists</z:chebi> for the PPARÎ³, administered prior or during ischemic insult improve <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome in rodents, post-occlusion treatments yielded inconsistent results </plain></SENT>
<SENT sid="1" pm="."><plain>In the present experiments carried out according to the <z:hpo ids='HP_0001297'>Stroke</z:hpo> Therapy Academic Industry Roundtable (STAIR) guidelines, we studied the effects of post-ischemic <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment on the outcome of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, inflammatory and apoptotic processes, <z:mp ids='MP_0002229'>neuronal degeneration</z:mp> and regeneration, blood pressure, heart rate and physiological variables in blood </plain></SENT>
<SENT sid="2" pm="."><plain>Male Wistar rats were subjected to a 90 min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>Subcutaneous (SC) treatment with vehicle or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> was initiated 90 min after MCAO, i.e. in the post-ischemic, reperfusion phase and continued on 2 (2 day-experiment, protocol 1) or 5 (5-day experiment, protocol 2) consecutive days </plain></SENT>
<SENT sid="4" pm="."><plain>In the 2-day experiment, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> at a dose of 2.5 mg/kg body weight (bw) reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 31% and <z:hpo ids='HP_0000969'>oedema</z:hpo> by 43% on day 2 after MCAO and attenuated the infiltration of ischemic cortical tissue with activated microglia and macrophages </plain></SENT>
<SENT sid="5" pm="."><plain>The slight reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by approximately 18%, detected in rats treated with 10 mg/kg bw <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> did not reach statistical significance </plain></SENT>
<SENT sid="6" pm="."><plain>The neurological scores of sham-operated rats treated with vehicle or 10 mg/kg bw <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> were not significantly different </plain></SENT>
<SENT sid="7" pm="."><plain>In rats subjected to <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, post-ischemic treatment with either dose of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> alleviated particular motor deficits and <z:hpo ids='HP_0003474'>sensory impairments</z:hpo> on day 2 after MCAO </plain></SENT>
<SENT sid="8" pm="."><plain>A single injection of 10 mg/kg bw <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in the reperfusion phase (90 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion) did not modify systolic and diastolic blood pressure, heart rate and physiological variables compared to vehicle-treated rats at any time point after MCAO </plain></SENT>
<SENT sid="9" pm="."><plain>In the 5-day experiment, continuous post-occlusion treatment with 2.5 mg/kg body weight <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> significantly reduced <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> by 29% and improved the partial <z:hpo ids='HP_0003470'>paralysis</z:hpo> of the forelimb and alleviated <z:e sem="disease" ids="C0748618" disease_type="Disease or Syndrome" abbrv="">sensory deficits</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> cortex, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> effectively suppressed the accumulation of activated microglia/macrophages, inhibited <z:mp ids='MP_0002229'>neuronal degeneration</z:mp> and promoted neuroregeneration and formation of neuronal networks </plain></SENT>
<SENT sid="11" pm="."><plain>The current results provide evidence that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment in the post-ischemic, reperfusion phase improves the recovery from <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Neuroprotective effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> are mediated by inhibition of post-ischemic <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0002229'>neuronal degeneration</z:mp>, protection of neurones against ischemic injury and by promoting of neuronal regeneration </plain></SENT>
<SENT sid="13" pm="."><plain>Our data together with previous findings favour the view that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> is a promising candidate for clinical <z:hpo ids='HP_0001297'>stroke</z:hpo> trials </plain></SENT>
</text></document>